Leukemic Infiltration of Myocardium Presenting as Cardiac Arrest

Torosyan, Nare; Mancera, Miguel S. Gonzalez; Tourtellotte, Warren G.; Kedan, Ilan

doi:10.1016/j.jaccas.2021.01.033

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 5–9% of peripheral blood cells in mice are granulocytes, of which the large majority are neutrophils, accounting for 30–40% of the mouse white blood cells . The plasticity of these myeloid-derived populations correlates with survival and controls the body’s immune defense. , In this study, the myeloid-derived CD11b + CD11c + and CD11b – CD11c + DCs and CD11b + Ly6C + Ly6G + PMN-MDSCs were upregulated in the blood after CAR. PMN-MDSCs are pathologically activated neutrophils and monocytes, which play a role in the immune response to injuries.…”

Section: Discussionmentioning

confidence: 63%

Fingerprint of Circulating Immunocytes as Biomarkers for the Prognosis of Brain Inflammation and Neuronal Injury after Cardiac Arrest

Dou,

Brandon,

Koper

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Cardiac arrest is one of the most dangerous health problems in the world. Outcome prognosis is largely based on cerebral performance categories determined by neurological evaluations. Few systemic tests are currently available to predict survival to hospital discharge. Here, we present the results from the preclinical studies of cardiac arrest and resuscitation (CAR) in mice to identify signatures of circulating immune cells as blood-derived biomarkers to predict outcomes after CAR. Two flow cytometry panels for circulating blood lymphocytes and myeloid-derived cells, respectively, were designed to correlate with neuroinflammation and neuronal and dendritic losses in the selectively vulnerable regions of bilateral hippocampi. We found that CD4 + CD25 + regulatory T cells, CD11b + CD11c − and CD11b + Ly6C + Ly6G + myeloid-derived cells, and cells positive for the costimulatory molecules CD80 and CD86 in the blood were correlated with activation of microglia and astrocytosis, and CD4 + CD25 + T cells are additionally correlated with neuronal and dendritic losses. A fingerprint pattern of blood T cells and monocytes is devised as a diagnostic tool to predict CAR outcomes. Blood tests aimed at identifying these immunocyte patterns in cardiac arrest patients will guide future clinical trials to establish better prognostication tools to avoid unnecessary early withdrawal from life-sustaining treatment.

show abstract

Section: Discussionmentioning

confidence: 63%

Fingerprint of Circulating Immunocytes as Biomarkers for the Prognosis of Brain Inflammation and Neuronal Injury after Cardiac Arrest

Dou,

Brandon,

Koper

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

Anatomic Approach to Common and Uncommon Manifestations of Thoracic Leukemias with Radiologic-Pathologic Correlation

Koo,

Frota Lima,

Kerper

et al. 2023

Radiology: Cardiothoracic Imaging

View full text Add to dashboard Cite

Acute Coronary Syndrome as an Unusual Initial Presentation of T‐Prolymphocytic Leukemia: A Case Report and Review of the Literature

Klein,

Jansen,

Brossart

et al. 2024

Case Reports in Hematology

View full text Add to dashboard Cite

T‐prolymphocytic leukaemia (T‐PLL) is the most common mature T‐cell leukaemia in Central Europe and is often manifested by rapidly increasing lymphocytosis, marked bone marrow infiltration and splenomegaly. In 10–15% of cases, the diagnosis is made by incidental findings in otherwise asymptomatic patients. Here we report a case of T‐PLL that initially became symptomatic due to the presence of acute coronary syndrome (ACS). Initially, emergency coronary angiography with consecutive emergency 5‐coronary artery bypass grafting (CABG) was performed. Leukocytosis was found perioperatively and T‐PLL (with TCL1 rearrangement) was subsequently diagnosed. Despite known potential cardiotoxicity, the patient was treated with the anti‐CD52 antibody alemtuzumab with a gradual dose increase from 3 mg to 30 mg per day. Systemic alemtuzumab therapy resulted in the complete remission of T‐PLL in the bone marrow without any impairment to cardiac function. The patient was then eligible to undergo a consolidating allogeneic stem cell transplant (alloSCT). The reported case shows that T‐PLL can also become initially symptomatic through an acute coronary syndrome on the basis of complex coronary heart disease. Targeted antileukaemic therapy with the monoclonal antibody alemzutumab can lead to effective systemic cytoreduction without cardiac dysfunction even in patients with severe cardiac disease, although cases of cardiotoxicity have been reported.

show abstract

Leukemic Infiltration of Myocardium Presenting as Cardiac Arrest

Cited by 3 publications

References 5 publications

Fingerprint of Circulating Immunocytes as Biomarkers for the Prognosis of Brain Inflammation and Neuronal Injury after Cardiac Arrest

Fingerprint of Circulating Immunocytes as Biomarkers for the Prognosis of Brain Inflammation and Neuronal Injury after Cardiac Arrest

Anatomic Approach to Common and Uncommon Manifestations of Thoracic Leukemias with Radiologic-Pathologic Correlation

Acute Coronary Syndrome as an Unusual Initial Presentation of T‐Prolymphocytic Leukemia: A Case Report and Review of the Literature

Contact Info

Product

Resources

About